Risk Factors Update Summary
- Addition of "biologic" to risk factors, reflecting expanded product scope. This change may impact regulatory approvals.
- Change from "partners" to "partner" emphasizes reliance on a single entity. This could increase risk.
- Introduction of "double positive" tumor infiltrating lymphocytes in clinical trials. This may impact trial outcomes.
- Shift from "collaborations" to "collaboration" highlights singular dependency. This could affect development timelines.
- Inclusion of "advanced solid tumors" expands trial scope. This may affect trial enrollment and outcomes.
- Change from "subjects" to "patients" clarifies trial enrollment. This may impact trial efficiency.
- Transition from "depend" to "rely" on third-party entities. This may affect trial conduct and outcomes.
Full Text Changes in Most Recent 10-K
Intended use: review the highlighted statements. These are additions to the risk factors disclosure in the most recent 10-K filing compared to the previous 10-K filing. Deleted and moved text is less important and is shown for context.
To view the full company filings, click on the following link to be taken to the SEC EDGAR database landing page for the company: https://www.sec.gov/edgar/browse/?CIK=1533040&owner=exclude
This content requires a 'Free' membership to view. Please create one here.
This content requires a 'Free' membership to view. Please create one here.